

Exome-wide association study reveals 7 functional variants associated with ex-vivo drug response in acute myeloid leukemia patients

Anil K Giri^{*1,2}, Jake Lin^{*1}, Konstantinos Kyriakidis¹, Garima Tripathi¹, Henrikki Almusa¹

¹Institute for Molecular Medicine Finland (FIMM), Helsinki Institute of Life Science, University of Helsinki, Helsinki, Finland.

²Foundation for the Finnish Cancer Institute (FCI), Tukholmankatu 8, 00290 Helsinki, Finland.

*Equal author

Correspondence to:

Anil K Giri, PhD

Institute for Molecular Medicine Finland (FIMM)

Biomedicum Helsinki

PO Box 20 (Haartmaninkatu 8)

FI-00014 University of Helsinki, Finland

Tel: +358 442431081

Email: anil.kumar@helsinki.fi

Abstract

Acute myeloid leukemia (AML) is a rare aggressive blood cancer without any long-term cure. Further, due to the extreme molecular heterogeneity of the disease, drug treatment response varies from patient to patient. The variability of drug response can cause unnecessary treatment in more

than half of the patients with no or partial therapy responses leading to severe side effects, economic as well as time loss. Understanding the genetic risk factors underlying the drug response in AML can help with improved prediction of treatment responses and identification of biomarkers in addition to mechanistic insights to monitor treatment response.

Here, we report the results of the largest exome-wide association study (EWAS) of ex-vivo drug response performed to date with 175 AML cases and 47 drugs. We used information from 55423 exonic SNPs to perform the analysis. We identified exome-wide significant ($p < 9.02 \times 10^{-7}$) associations for rs113985677 in *CCIN* with tamoxifen response, rs115400838 in *TRMT5* with idelalisib response, rs11878277 in *HDGFL2* with entinostat, and rs2229092 in *LTA* associated with vorinostat response.

Further, using multivariate genome-wide association analysis, we identified the association of rs11556165 in *ATRAID*, and rs11236938 in *TSKU* with the combined response of all 47 drugs and 29 nonchemotherapy drugs at the genome-wide significance level ($p < 5 \times 10^{-8}$). Additionally, a significant association of rs35704242 in *NIBANI* was associated with the combined response for nonchemotherapy medicines ($p = 2.51 \times 10^{-8}$), and BI.2536, gefitinib, and belinostat were identified as the central traits. Our study represents the largest EWAS study to date on ex-vivo drug response in AML and reports 7 new associated loci that help to understand the anticancer drug response in AML patients.

Introduction

Acute myeloid leukemia (AML) is a biologically heterogeneous aggressive hematological malignancy^{1,2}. The inherent heterogeneity not only influences the clinical presentation of the disease but also affects the response and toxicity towards a therapy^{3,4}. Hence, huge interindividual variability exists for drug response in AML patients^{5,6,7}.

The variability in the treatment response of AML patients is driven by a broad spectrum of genetic (e.g., somatic and germline variants) and nongenetic alterations (e.g., age) present in different patient groups.⁸ Although the somatic mutations affecting treatment response in AML have been extensively studied in AML^{9,10}, the germline variants contributing to the drug response largely remain under-explored mostly because of a lack of well-characterized cohorts with both genetic and

drug treatment data¹¹⁻¹³. Further, the number of drug-treatment that can be explored in a clinical cohort is limited because patients are usually treated with one or two common drugs approved in the clinics, hence neglecting the other drugs. Furthermore, the collection of clinical responses to drugs in a large patient cohort will require long follow-up time, resources, and a network that could be beyond the capability of most academic laboratories.

The drug sensitivity and resistance testing (DSRT) platform can measure the ex-vivo response for hundreds of drugs at multiple doses in patient-derived primary cells¹⁴⁻¹⁶. The ex-vivo drug response can provide a reasonable estimate for the clinical response of the patient towards the drug^{3,9} and has been increasingly used in guiding the treatment for refractory/relapse patients with no available standardized treatment. Further, the ex-vivo drug response measured in patient-derived-primary samples has been used as a surrogate for clinical response to identify genetic variants affecting treatment response in a patient.

Here, using the germline information from the exome-sequencing and ex-vivo response data from 47 drugs measured in 75 AML patients, we performed an exome-wide association study to identify functional variants affecting drug response in AML. The result identifies 4 novel loci near *CCIN*, *TRMT5*, *HDGFL2*, and *LTA* genes affecting the ex-vivo response of tamoxifen, idelalisib, entinostat, and vorinostat in AML at exome-wide significance levels. Further, we also used a novel and efficient statistical framework “MetaPhat” to conduct and decompose multivariate GWAS signals affecting ex-vivo drug response in AML patients. The analysis identified the association of loci in *NIBANI*/, *ATRAID*, and *TSKU* with combined drug response in AML.

Methods

AML Patient’s cohort

One seventy-five bone marrow aspirates and peripheral blood samples (leukemic cells) and skin biopsies (noncancerous cells for germline genomic information) from high-risk AML patients were obtained after informed consent with approval (No. 239/13/03/00/2010, 303/13/03/01/2011). Patient characteristics are summarized in Supplementary Table 1.

Exome-sequencing of the samples

Genomic DNA was isolated from the skin biopsies samples using the DNeasy Blood & Tissue Kit (Qiagen) and was used for exome sequencing. For exome sequencing, 3 µg DNA was fragmented and processed according to the NEBNext DNA Sample Prep Master Mix protocol. Exome capture was performed using the Nimblegen SeqCap EZ v2 capture Kit (Roche NimbleGen). Sequencing of exomes was done using HiSeq1500, 2000, or 2500 instruments (Illumina) and approximately 4×10^7 bp paired-end reads were sequenced per sample. The data was curated and analyzed as described before^{9, 17}.

Briefly, the sequenced raw exome reads were trimmed using Trimmomatic (version 0.36) to remove adapters and low-quality segments. The trimmed data were aligned to the human reference genome (GRCh build 37) using Burrows-Wheeler Aligner (bwa version 0.7.12, Wellcome Trust Sanger Institute, Cambridge, UK). After alignment, the potential PCR duplicates were removed using Picard (Broad Institute of Harvard and MIT, Cambridge, MA, USA), and BAM files were sorted, and indexed using SAMtools (Wellcome Trust Sanger Institute, Cambridge, UK). From the aligned

reads, GATK (version 4.1.3.0) was used to joint call the samples for genetic variants. Variant annotation was performed using ANNOVAR and Ensembl version 6851.

We performed a stringent quality control analysis of the genetic data (Supplementary Figure 1). We removed 1 sample with a genomic call rate of less than 95%, and 9 samples with missing information for >10 of the drug response. We also removed variants without proper annotation (without rsid), call rate (<90%), MAF <0.01, and Hardy Weinberg equilibrium p-value $< 10^{-5}$ were removed.

Drug resistance and sensitivity testing: We measured ex-vivo response for a library of 47 commercially available chemotherapeutic and targeted oncology compounds consisting of 34 approved drugs, and 13 investigation compounds (Supplementary Table 2) using the DSRT platform at the high throughput biomedicine unit at FIMM as described before^{14,18}. Briefly, drugs were plated in a 10-fold dilution series of five concentrations covering a 1,000-fold concentration range on clear-bottomed 384-well plates (Corning #3712), using an Echo 550 Liquid Handler (Labcyte). The concentration ranges were selected for each compound separately to investigate their full dynamic range of the dose-response relationships.

Next, 20 μ l of AML cells (approximately 10,000) was added to a pre-drugged plate containing the mononuclear cell medium (MCM; PromoCell) supplemented with 0.5 μ g/mL gentamicin and 2.5 μ g/mL amphotericin B^{3,18}. The cell was maintained in the culture media at 37 °C with 5% CO₂ in a humidified incubator. After 72h incubation, cell viability was measured using CellTiter-Glo (Promega) reagent in duplicate using a PHERAstar FS (BMG Labtech) plate reader. As positive (total killing) and negative (non-effective) controls, we used 100 μ M benzethonium chloride and 0.1% dimethyl sulfoxide (DMSO), respectively, when calculating the relative inhibition percent.

The percentage inhibition was calculated by normalizing the cell viability to negative control wells containing only 0.1% dimethyl sulfoxide (DMSO) and positive control wells containing 100 μ M cell-killing benzethonium chloride (BzCl). The drug responses passing the data quality assessment were included in further analysis. Drug sensitivity score (DSS), a measure of drug efficacy for each drug was calculated for each patient as described before¹⁹. Next, selective DSS (sDSS) was calculated by normalizing drug responses against 17 healthy controls.

Single SNP exome-wide association analysis: We only selected 47 drugs for an analysis whose ex-vivo response was measured in all the patients. The sDSS scores for each drug were inverse normalized using the inbuilt command in R (<http://www.r-project.org/>). We performed a linear regression model using PLINK²⁰ to test the association of SNPs with inverse normalized sDSS. Cell culture medium for the drug assay, disease stage (relapse/diagnosis), and first five principal components were used as covariates in the model. All other statistical analyses and plotting were performed using R programming. We used the Bonferroni correction for multiple tests ($n = 55423$ tests) and set the statistical significance and suggestive threshold to P-values less than 9.02×10^{-7} and 1×10^{-4} , respectively.

Multivariate exome-wide association analysis using MetaPhat: Several of the drugs measured in the experiment have a similar mechanism of action and act through the same pathway. As these functionally similar drugs have a correlated response in the studied samples, we used our novel method to conduct multivariate EWAS of a linear combination of correlated traits using univariate GWAS for 55423 SNPs results as implemented in MetaPhat²¹ (integrating metaCCA²²). Further, we decomposed the multivariate associations into sets of central biomarker traits to understand the possible mechanism of action for the identified variant. This analysis tested each SNP separately for its simultaneous associations with all 47 phenotypes, 18 chemotherapies, and 29 nonchemotherapies drugs. A multivariate approach had the dual advantages of achieving data reduction and increasing statistical power compared with running 47 separate univariates EWAS.

Since we did not have a replication cohort, we performed a statistical experiment to validate the true nature of identified association in multivariate EWAS by estimating the chance of observing such an association in a random dataset. For this, we assigned random patient identity to each row of the phenotype file while keeping the correlation between the drug response the same and performed the univariate and multivariate association analysis with the genotypes using the same parameters.

Results

Single SNP association with the ex-vivo drug response identified association of 4 locus at exome-wide significance level

After stringent quality control, we analyzed a total of 55423 genetic markers for their association with single-drug response in 175 AML patients using linear regression adjusting for gender, age (at diagnosis for cases), cell culture medium, and the first 10 principal components. We detected an exome-wide significance level association for rs113985677 in *CCIN* with Tamoxifen ($p=3.68 \times 10^{-07}$), and rs115400838 in *TRMT5* with the idelalisib response ($p=4.20 \times 10^{-7}$). We also observed an EWAS level significance for rs11878277 in *HDGFL2* with entinostat ($p=4.94 \times 10^{-7}$), and rs2229092 in *LTA* with vorinostat response ($p=8.28 \times 10^{-7}$) (Table 1). The distribution of the association p-value across different chromosomes have been shown in Figure 1.

A good agreement was observed between the theoretical p-value distribution and calculated p-values for these drugs as shown in Supplementary Figure 2. The genomic inflation factor (λ) for the fitted model ranges between 0.98-1.01 which indicates the homogeneity of analyzed samples.

Table1: SNPs showing association with ex-vivo drug response at exome-wide significance levels in the analysis.

CHR	POS	SNP	Position	Gene	A1/A2	N	Effect size	P	Phenotype	Mechanism	Approval status
9	36170290	rs113985677	Missense R (Arg) > Q/p (Gln/Pro)	<i>CCIN</i>	A/G	175	4.45 (0.84)	3.68×10^{-7}	Tamoxifen	Selective estrogen receptor modulator	Approved
14	61446147	rs115400838	Missense R (Ser) > P (Cys)	<i>TRMT5</i>	A/T	175	7.58(1.44)	4.20×10^{-7}	Idelalisib	PI3K inhibitor	Approved
19	4498000	rs11878277	Synonymous S (Ser) > S (Ser)	<i>HDGFL2</i>	A/G	175	10.23(1.96)	4.94×10^{-7}	Entinostat	HDAC inhibitor	Phase 2

6	31572980	rs2229092	Missense H (His) > P (Pro)	LTA	C/A	173	-4.9(1)	8.28x10 ⁻⁷	Vorinostat	HDAC inhibitor	Approved
---	----------	-----------	----------------------------------	-----	-----	-----	---------	-----------------------	------------	-------------------	----------

Chromosomal positions of SNPs are based on National Center for Biotechnology Information genome build 38. The effect size was calculated with respect to the minor alleles. The association results presented were obtained from genotyped data in 175 patients.

Suggestive association in exome-wide association analysis

Further, we observed associations of SNPs with the response of multiple drugs with a similar mechanism of action at the sub-EWAS level of significance ($P < 10^{-4}$) suggesting a true nature of the association. For example, we observed the association of SNPs in the same genes with drugs having similar mechanisms of action. For example, rs2394516 and rs2394516 in *OR2J1* (olfactory receptor 2J1) were associated with both cladribine (purine analog) and clofarabine (another purine analog) suggesting a similar mechanism for influencing the drug response by identified variants (Supplementary Table 3).

Similarly, associations of rs201274224 in *PIK3CD* were observed with daunorubicin (topoisomerase II inhibitor), idarubicin (topoisomerase II inhibitor), and fludarabine (a purine analog) response suggesting a common mechanism of action probably through DNA damage and repair pathways. In total, we observed 295 suggestive associations within 248 unique SNP associated with the 47-drug response (Supplementary Figure 3, Supplementary Table 3).

Multi-variate association analysis identified an association of 4 additional SNPS at the exome-wide significance level

In the multivariate analysis, first, we checked the association of 55423 SNPs with a combined response of 47 drugs (Supplementary Figure 4) and observed a GWAS level association for rs11236938-G/A (*TSKU*) with the combined response ($p = 2.51 \times 10^{-9}$, Figure 2a, Supplementary Table 4). Further, the decomposition of multivariate association identified tamoxifen, BI.2536, and belinostat as the central traits, as defined by optimal Bayesian Information Criteria (BIC)²³ subset and union with traits iteratively driving significant p-value for the multivariate association. Further, the analysis also identified an association of rs11556165-*ATRAID* ($p = 4.26 \times 10^{-8}$, Supplementary Table 4) with the combined response of belinostat, fingolimod, and alvocidib as the central traits at the genome-wide significance level.

Next, we also performed multivariate analysis to check the association of SNPs with only a group of drugs with specific mechanisms of action (e.g., kinase inhibitors). The analysis of response from the 29 non-chemotherapy drugs identified an association of rs11236938-G/A in *TSKU* with combined drug response and tamoxifen, BI.2536, and belinostat ($p = 3.8 \times 10^{-11}$, Figure 2b, Table 2) as the central trait. Further, rs11556165-*ATRAID* was also associated with EWAS significance level ($p = 3.98 \times 10^{-9}$) with the combined response of non-chemo drugs with belinostat, fingolimod, alvocidib as the major trait. Similarly, rs35704242-C/T in *NIBANI* was associated with the combined nonchemotherapy drug response and, BI.2536, gefitinib, and belinostat as the main traits ($p = 2.51 \times 10^{-8}$). The observed inflation factor for the p-values were 1.3 for all drug analysis and 1.17 for only nonchemotherapy drug response analysis (Supplementary Figure 5)

Table 2: SNPs showing association with ex-vivo response of nonchemotherapy drugs as group at genome-wide significance levels in the multivariate analysis.

CHR	BP	Variant (Gene)	Allele	MAF	Pval	Central traits	Drug group
11	76507403	rs11236938-G/A (<i>TSKU</i>)	S (Ser) > N (Asn)	0.03	3.8×10^{-11}	Tamoxifen, BI.2536, Belinostat	Non chemotherapy
2	27438615	rs11556165-G/C (<i>ATRAID</i>)	D (Asp) > H (His)	0.04	3.98×10^{-9}	Belinostat, Fingolimod, Alvocidib	Non chemotherapy
1	184764824	rs35704242-C/T (<i>NIBANI</i>)	D (Asp) > N (Asn)	0.04	2.51×10^{-8}	BI.2536, Gefitinib, Belinostat	Non chemotherapy

Validation of the identified association: To check the validity of the association and significance level of the p-value, we also performed an association analysis by creating 200 sets of randomized phenotypes (200x47 phenotypes) where we kept the correlation between responses of the 47 drugs the same. The univariate association analysis did not identify any signals at the exome-wide significance level at any of the random phenotypes.

However, only 8 out of 200 times any exome-wide significant association was observed when the response of all 47 drugs was analysed in the multivariate analysis. Similarly, only 5 EWAS-level significant associations were observed out of 200 times when only the response of 29 non-chemo drugs were analysed together. These analyses firmly ascertain the true nature of identified associations and revealed a maximum of 4% chance of the identified signals as false positive.

Discussion

Genetic risk factors affecting the response of most cancer drugs are poorly defined^{24,25}. Most of the large-scale genomics study in AML has explored the effect of somatic mutations on drug response undermining the influence of germline variant except for a few drugs^{26,27}. Further, these studies exploring the effect of the germ-line variants on drug response have only analyzed the polymorphisms in genes encoding transporters, metabolizers, or molecular targets of chemotherapy agents neglecting most parts of the genomes^{12,28}. Although specific somatic mutations have been associated with the drug response for some of the targeted therapy, such mutations account for only a minority of cases and the great majority of patients does not have such clear marker²⁷. The large amount of time and resources required to collect the clinical response data has been one of the major obstacles to performing large, genome-wide association studies to identify pharmacogenetic variants affecting drug response. Our study, which comprised over 175 AML cases profiled for an ex-vivo response of 47 drugs, represents one of the largest such studies performed to date.

We identified 4 EWAS significant variants affecting the ex-vivo drug response in our cohort overall using the univariate association analysis. However, we could not validate these signals because of the lack of other cohorts having this kind of data. We identified the association of rs113985677, a missense variant (changes arginine to glutamine or proline) in *CCIN* (calcin) with Tamoxifen ex-vivo response. Calcin is a cytoskeleton protein and has been associated with lateral sinus thrombosis, spermatogenic Failure 9, globozoospermia^{29,30} and is required for the formation of the sperm head and maintain the nuclear structure in mice³¹. Downregulation of the cytoskeleton genes, connexin 43, induces tamoxifen-resistance in breast cancer³² cells via activation of c-Src/PI3K/Akt signaling and Epithelial to mesenchymal transition (EMT) of cells. The identified variant in the calcin gene may alter the tamoxifen response by altering the cytoskeleton dynamics during EMT.

Further, the variant is an expression quantitative trait locus for *GLIPR2* gene in the esophagus and salivary gland ($P=6.5 \times 10^{-12}$, and 7.9×10^{-8}) where the presence of alternate allele is associated with increased expression of *GLIPR2*. *GLIPR2* is particularly expressed in leukocytes and has a role in EMT transition³³, and autophagy³⁴, suggesting a possible role in drug response via these mechanisms. However, a functional study will be needed to understand the exact role of genes and variants.

We also found a significant association between rs115400838, an upstream variant in *SLC38A6*, and a missense variant in *TRMT5* with an idelalisib response. *SLC38A6* is a glutamine and glutamate transporter³⁵ and has been associated with angiotensin-converting enzyme inhibitor-induced cough³⁶. The available evidence suggests that *SLC38A6* may be a direct transporter of idelalisib itself or its substrates. We also observed a significant association of rs11878277 (*HDGFL2*) with entinostat in the univariate analysis. Entinostat is a histone deacetylase inhibitor and is under clinical trial for multiple cancers. *HDGFL2* (Hepatoma-Derived Growth Factor-Related Protein 2) is dispensable for Mixed Lineage Leukemia (MLL)-rearranged (MLL-R) leukemogenesis³⁷ and regulates gene expression via HRP2-DPF3a-BAF complex formation³⁸.

Similarly, a significant association was observed for a missense variant rs2229092 (H (His) > P (Pro) in Lymphotoxin Alpha (*LTA*) gene with vorinostat response, an HDAC inhibitor. *LTA*, formerly known as tumor necrosis factor-beta (TNF- β) is a toxin produced from lymphocytes (e.g., T and B) that can kill other cell types. It acts as a causative factor for autocrine and paracrine activation of canonical and noncanonical NF- κ B signaling as well as promotes JAK2/STAT6 signaling in Hodgkin lymphoma³⁹ resulting in prevention of apoptosis. Furthermore, *LTA* shapes the expression of lymphoid and myeloid-specific genes in blood. Given the wide role of *LTA* in immunity and tumor survival⁴⁰, *LTA* may influence vorinostat response by modulating cancer survival-related gene expression in synergy with vorinostat.

The multivariate analysis identified rs11556165-*ATRAID* as one of the significant SNPs at EWAS level. *ATRAID* (all-trans retinoic acid-induced differentiation factor), is a genetic target of nitrogen-containing-bisphosphonates (N-BP), a commonly used drug to treat osteoporosis and other bone-related diseases^{41, 33}. Further, *ATRAID* binds with *SLC37A3* (solute carrier family 37 member A3) which is a lysosomal membrane protein with 12 transmembrane segments and helps in NBP transport.

The multivariate analysis identified rs11556165-*CAD* (carbamoyl-phosphate synthetase 2, aspartate transcarbamylase, and dihydroorotase) as one of the significant SNPs at EWAS level (Table 2). *CAD* protein is a multifunctional multi-domain enzyme involved in the initial three speed-limiting steps of pyrimidine nucleotide synthesis. *CAD* is hyperactivated in most of the cancer and targeting it inhibits cancer cell survival, and self-renewal⁴¹.

Genetic target of nitrogen-containing-bisphosphonates (N-BP), a commonly used drug to treat osteoporosis and other bone-related diseases^{41,42}. Further, ATRAID binds with *SLC37A3* (solute carrier family 37 member A3) which is a lysosomal membrane protein with 12 transmembrane segments and helps in NBP transport⁴¹.

We also identified the association of rs35704242 in niban apoptosis regulator 1 (*NIBAN1*) multi-drug response with BI 2536, gefitinib, and belinostat as the central trait set. *NIBAN1* protein is highly expressed in multiple cancers such as such as renal, colorectal, and thyroid cancer^{43,44} and may play an important role in cell survival during cellular stress such as ultraviolet irradiation cell migration and proliferation⁴³, cell autophagy⁴⁵ and immune microenvironment⁴⁶. The association of BI 2536, gefitinib, and belinostat central responses which induce induces cell cycle, and apoptosis of cancer cells with *NIBAN1* align with the versatile function of *NIBAN1* in cellular homeostasis seems justifiable.

We also observed a significant association of tsukushi (*TSKU*), a small leucine-rich proteoglycan, with overall kinase ($p=2.51 \times 10^{-8}$) with Tamoxifen, BI.2536, Belinostat as the central traits. Tsukushin is an extracellular matrix protein and is also a hepatokine. *TSKU* is involved in different signaling pathways including BMP pathway, notch pathway, transforming growth factor- β (TGF- β) pathway, mitogen-activated protein kinase (MAPK)/fibroblast growth factor (FGF) pathway, and β -catenin/Wnt pathway⁴⁷. Absence of *TSKU* increases cleaved poly ADP-ribose polymerase (PARP) protein levels and caspase 3/7 activity thereby increasing carcinogenicity in neuroblastoma cells⁴⁸. Further, *TSKU* expression is strongly associated with poor overall survival in lung cancer⁴⁹. Given its role in carcinogenicity and tumor survival, *TSKU* may affect drug response in cancer. However, further functional study is needed to reveal the exact mechanism by which *TSKU* affects drug response in AML.

In summary, our exome-wide analysis identified a potential genetic locus affecting the ex-vivo drug response of some of the common cancer therapy. These loci are in proximity to genes with a possible role in the transport of the respective drugs inside the cell. Our results provide a basis for initial exploration of the role of genes associated with this locus. However, replication studies to confirm the observed associations are needed in larger patient-group. However, the lack of another cohort for validation is a major limitation of the study. Though being a novel and significantly large cohort for a rare disease like AML, our study is still smaller than genome-wide association studies reported in other malignancies and is potentially limited in its power to detect associations. Additionally, in light of the increasing evidence that AML tumors are genetically heterogeneous, genetic predisposing factors likely vary across patients. Although we attempted to address this potential weakness by performing correlation based MetaPhat analysis, these analyses are based on drugs with different targets and mechanisms of action, resulting in the potential to miss associations due to the lack of statistical power.

Reference

1. Cancer Genome Atlas Research N, Ley TJ, Miller C, Ding L, Raphael BJ, Mungall AJ, *et al*. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. *N Engl J Med* 2013 May 30; **368**(22): 2059-2074.
2. Quek L, David MD, Kennedy A, Metzner M, Amatangelo M, Shih A, *et al*. Clonal heterogeneity of acute myeloid leukemia treated with the IDH2 inhibitor enasidenib. *Nat Med* 2018 Aug; **24**(8): 1167-1177.

3. Ianevski A, Lahtela J, Javarappa KK, Sergeev P, Ghimire BR, Gautam P, Vähä-Koskela M, Turunen L, Linnavirta N, Kuusanmäki H, Kontro M, Porkka K, Heckman CA, Mattila P, Wennerberg K, Giri AK, Aittokallio T. Patient-tailored design for selective co-inhibition of leukemic cell subpopulations. *Sci Adv.*, **7**(8):eabe4038 (2021).
4. Giri, A.K., Ianevski, A. & Aittokallio, T. Genome-wide off-targets of drugs: risks and opportunities. *Cell Biol Toxicol* **35**, 485-487 (2019).
5. Daver N, Garcia-Manero G, Basu S, Boddu PC, Alfayez M, Cortes JE, *et al.* Efficacy, Safety, and Biomarkers of Response to Azacitidine and Nivolumab in Relapsed/Refractory Acute Myeloid Leukemia: A Nonrandomized, Open-Label, Phase II Study. *Cancer Discov* **9**, 370-383 (2019).
6. Giri A.K., Ianevski, A. High-throughput screening for drug discovery targeting the cancer cell-microenvironment interactions in hematological cancers. *Expert Opin Drug Discov.* **17**, 181-190 (2021)
7. Schroeder T, Rautenberg C, Kruger W, Platzbecker U, Bug G, Steinmann J, *et al.* Treatment of relapsed AML and MDS after allogeneic stem cell transplantation with decitabine and DLI-a retrospective multicenter analysis on behalf of the German Cooperative Transplant Study Group. *Ann Hematol* **97**, 335-342 (2018).
8. Bottomly, D., *et al.* Integrative analysis of drug response and clinical outcome in acute myeloid leukemia. *Cancer Cell* **40**, 850-864 e859 (2022).
9. Malani, D., *et al.* Implementing a Functional Precision Medicine Tumor Board for Acute Myeloid Leukemia. *Cancer Discov* **12**, 388-401 (2021).
10. Tyner JW, Tognon CE, Bottomly D, Wilmot B, Kurtz SE, Savage SL, *et al.* Functional genomic landscape of acute myeloid leukaemia. *Nature* **562**, 526-531 (2018).
11. Williams MS, Amaral FM, Simeoni F, Somerville TC. A stress-responsive enhancer induces dynamic drug resistance in acute myeloid leukemia. *J Clin Invest*; **130**: 1217-1232 (2020).
12. Lamba JK. Genetic factors influencing cytarabine therapy. *Pharmacogenomics* **10**, 1657-1674 (2009).
13. Zhu KW, Chen P, Zhang DY, Yan H, Liu H, Cen LN, *et al.* Association of genetic polymorphisms in genes involved in Ara-C and dNTP metabolism pathway with chemosensitivity and prognosis of adult acute myeloid leukemia (AML). *J Transl Med*, **16**: 90 (2018).
14. Ianevski, A., Giri, A.K., Gautam, P. *et al.* Prediction of drug combination effects with a minimal set of experiments. *Nat Mach Intell* **1**, 568–577 (2019).
15. Ianevski, A., Giri, A.K. & Aittokallio, T. SynergyFinder 3.0: an interactive analysis and consensus interpretation of multi-drug synergies across multiple samples. *Nucleic Acids Res* **50**, W739–43 (2022).
16. Ianevski, A., Giri, A.K. & Aittokallio, T. SynergyFinder 2.0: visual analytics of multi-drug combination synergies. *Nucleic Acids Res* **48**, W488-W493 (2020).
17. Wahnschaffe L, Braun T, Timonen S, Giri AK, Schrader A, Wagle P, *et al.* JAK/STAT-Activating Genomic Alterations Are a Hallmark of T-PLL. *Cancers (Basel)* 2019 Nov 21; **11**(12).
18. Ianevski A, Timonen S, Kononov A, Aittokallio T, Giri AK. SynToxProfiler: An interactive analysis of drug combination synergy, toxicity and efficacy. *PLoS Comput Biol* 2020 Feb; **16**(2): e1007604.

19. Yadav B, Pemovska T, Szwajda A, Kuleskiy E, Kontro M, Karjalainen R, *et al.* Quantitative scoring of differential drug sensitivity for individually optimized anticancer therapies. *Sci Rep* 2014 Jun 5; **4**: 5193.
20. Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MA, Bender D, *et al.* PLINK: a tool set for whole-genome association and population-based linkage analyses. *Am J Hum Genet* 2007 Sep; **81**(3): 559-575.
21. Lin J, Tabassum R, Ripatti S, Pirinen M. MetaPhat: Detecting and Decomposing Multivariate Associations From Univariate Genome-Wide Association Statistics. *Front Genet* 2020; **11**: 431.
22. Cichonska, A., *et al.* metaCCA: summary statistics-based multivariate meta-analysis of genome-wide association studies using canonical correlation analysis. *Bioinformatics* **32**, 1981-1989 (2016).
23. Schwarz G. Estimating the Dimension of a Model. *Ann. Statist.* **6**(2): 461-464 (1978).
24. Menden MP, Casale FP, Stephan J, Bignell GR, Iorio F, McDermott U, *et al.* The germline genetic component of drug sensitivity in cancer cell lines. *Nat Commun* 2018 Aug 23; **9**(1): 3385.
25. Hariprakash JM, Vellarikkal SK, Keechilat P, Verma A, Jayarajan R, Dixit V, *et al.* Pharmacogenetic landscape of DPYD variants in south Asian populations by integration of genome-scale data. *Pharmacogenomics* 2018 Feb; **19**(3):227-241.
26. Little P, Lin DY, Sun W. Associating somatic mutations to clinical outcomes: a pan-cancer study of survival time. *Genome Med* 2019 May 28; **11**(1): 37.
27. Levatic, J., Salvadores, M., Fuster-Tormo, F. & Supek, F. Mutational signatures are markers of drug sensitivity of cancer cells. *Nat Commun* **13**, 2926 (2022).
28. Huang RS, Duan S, Kistner EO, Bleibel WK, Delaney SM, Fackenthal DL, *et al.* Genetic variants contributing to daunorubicin-induced cytotoxicity. *Cancer Res* 2008 May 1; **68**(9): 3161-3168.
29. Celse T, Cazin C, Mietton F, Martinez G, Martinez D, Thierry-Mieg N, *et al.* Genetic analyses of a large cohort of infertile patients with globozoospermia, DPY19L2 still the main actor, GGN confirmed as a guest player. *Hum Genet* 2021 Jan; **140**(1): 43-57.
30. Li YZ, Wu RF, Zhu XS, Liu WS, Ye YY, Lu ZX, *et al.* Identification of a novel deletion mutation in DPY19L2 from an infertile patient with globozoospermia: a case report. *Mol Cytogenet* 2020; **13**: 24.
31. Zhang, X.Z., Wei, L.L., Jin, H.J., Zhang, X.H. & Chen, S.R. The perinuclear theca protein Calicin helps shape the sperm head and maintain the nuclear structure in mice. *Cell Rep* **40**, 111049 (2022).
32. Wu, D.P., *et al.* Cx43 deficiency confers EMT-mediated tamoxifen resistance to breast cancer via c-Src/PI3K/Akt pathway. *Int J Biol Sci* **17**, 2380-2398 (2021).
33. Huang, S., *et al.* GLIPR-2 overexpression in HK-2 cells promotes cell EMT and migration through ERK1/2 activation. *PLoS One* **8**, e58574 (2013).
34. Aalberts, M., *et al.* Identification of distinct populations of prostasomes that differentially express prostate stem cell antigen, annexin A1, and GLIPR2 in humans. *Biol Reprod* **86**, 82 (2012).
35. Gandasi NR, Arapi V, Mickael ME, Belekara PA, Granlund L, Kothegala L, *et al.* Glutamine Uptake via SNAT6 and Caveolin Regulates Glutamine-Glutamate Cycle. *Int J Mol Sci* 2021 Jan 25; **22**(3).

36. Hallberg P, Persson M, Axelsson T, Cavalli M, Norling P, Johansson HE, et al. Genetic variants associated with angiotensin-converting enzyme inhibitor-induced cough: a genome-wide association study in a Swedish population. *Pharmacogenomics*. 2017 Feb;**18**(3):201-213..
37. Van Belle S, El Ashkar S, Cermakova K, Matthijssens F, Goossens S, Canella A, et al. Unlike Its Paralog LEDGF/p75, HRP-2 Is Dispensable for MLL-R Leukemogenesis but Important for Leukemic Cell Survival. *Cells* 2021 Jan 19; **10**(1).
38. Zhu X, Lan B, Yi X, He C, Dang L, Zhou X, et al. HRP2-DPF3a-BAF complex coordinates histone modification and chromatin remodeling to regulate myogenic gene transcription. *Nucleic Acids Res*; **48**(12): 6563-6582.
39. von Hoff L, Kärigel E, Franke V, McShane E, Schulz-Beiss KW, Patone G, et al. Autocrine LTA signaling drives NF- κ B and JAK-STAT activity and myeloid gene expression in Hodgkin lymphoma. *Blood*.**133**(13):1489-1494 (2019).
40. Fhu, C.W., et al. Reed-Sternberg cell-derived lymphotoxin- α activates endothelial cells to enhance T-cell recruitment in classical Hodgkin lymphoma. *Blood* **124**, 2973-2982 (2014).
41. Yu Z, Surface LE, Park CY, Horlbeck MA, Wyant GA, Abu-Remaileh M, et al. Identification of a transporter complex responsible for the cytosolic entry of nitrogen-containing bisphosphonates. *Elife* 10; **7** (2018).
42. Surface LE, Burrow DT, Li J, Park J, Kumar S, Lyu C, et al. *ATRAID* regulates the action of nitrogen-containing bisphosphonates on bone. *Sci Transl Med*, **12**(544):eaav9166 (2020).
43. Feng, X., et al. miR-4521-FAM129A axial regulation on ccRCC progression through TIMP-1/MMP2/MMP9 and MDM2/p53/Bcl2/Bax pathways. *Cell Death Discov* **5**, 89 (2019).
44. Diana, P. & Carvalheira, G.M.G. NIBAN1, Exploring its Roles in Cell Survival Under Stress Context. *Front Cell Dev Biol* **10**, 867003 (2022).
45. Ji, H., et al. AKT-dependent phosphorylation of Niban regulates nucleophosmin- and MDM2-mediated p53 stability and cell apoptosis. *EMBO Rep* **13**, 554-560 (2012).
46. Zhang, R., et al. Tissue Treg Secretomes and Transcription Factors Shared With Stem Cells Contribute to a Treg Niche to Maintain Treg-Ness With 80% Innate Immune Pathways, and Functions of Immunosuppression and Tissue Repair. *Front Immunol* **11**, 632239 (2020).
47. Deng, X., Li, Y., Guo, C., Zhao, Z. & Yuan, G. Novel roles of Tsukushi in signaling pathways and multiple disease processes. *Biofactors* **47**, 512-521 (2021).
48. Ichikawa, T., Horie-Inoue, K., Ikeda, K., Blumberg, B. & Inoue, S. Steroid and xenobiotic receptor SXR mediates vitamin K2-activated transcription of extracellular matrix-related genes and collagen accumulation in osteoblastic cells. *J Biol Chem* **281**, 16927-16934 (2006).
49. Huang H, Zhang D, Fu J, Zhao L, Li D, Sun H, et al. Tsukushi is a novel prognostic biomarker and correlates with tumor-infiltrating B cells in non-small cell lung cancer. *Aging* (Albany NY). 10;13(3):4428-4451 (2021).

Figure legends




Figure 1: Manhattan plot depicting the $-\log(10)$ p-values for SNPs associated with (a) tamoxifen (b) idelalisib, (c) entinostat, and (d) vorinostat across different chromosomes. The p-value has been obtained using linear regression adjusted for disease stage (diagnosis/relapse), cell culture medium and first 5 principal components from genotype data.





Figure 2: Multivariate association analysis of exonic SNPs with the linear combination of drug response (a) Heatmap showing the correlation between the analyzed drugs based on the response from the 175 patients. (b) Manhattan plot depicting the $-\log(10)$ p-values for SNPs associated with all 47 drugs across different chromosomes in multivariate analysis. (c) Manhattan


plot depicting the $-\log(10)$ p-values for SNPs associated with only kinase inhibitors (d)Heatmap showing the importance of each kinase inhibitor response on the association of identified signals (The increase of importance has been shown from red to blue).

Supplementary Information


Supplementary Figure 1: Flow-chart for the SNP and sample quality control



Supplementary Figure 2: QQ plot for the univariate GWAS associations





Supplementary Figure 3: The number of associations observed for each trait at sub exome wide significance level ($p < 10^{-4}$).






Supplementary Figure 4: QQ plot for the multivariate analysis

rs35704242




rs11556165





Supplementary Figure 5: QQ plot for the multivariate analysis



Supplementary Table 1: Details of the analyzed drugs and their mechanism of action

Trait	Diagnosis (N=108)	Relapsed/refractory (n=67)
Culture medium (MCM/CM)	82/26	46/21
Age (median, range)	64(21-81)	60(19-76)

Sex (M/F/NA)	45/55/8	20/23/24
--------------	---------	----------

NA: Not available,

Supplementary Table 2: Details of the analyzed drugs and their mechanism of action

SN	Drug	Mechanism/Targets	Class.explained	High.phase/Approval.status	Solvent	High.conc (nM)
1	Tamoxifen	Estrogen receptor antagonist	F. Hormone therapy	Approved	DMSO	10000
2	Navitoclax	Bcl-2/Bcl-xL inhibitor	G. Apoptotic modulator	Investigational (Ph 2)	DMSO	10000
3	Belinostat	HDAC inhibitor	E. Differentiating/epigenetic modifier	Approved (US)	DMSO	10000
4	Dactolisib	mTOR/(PI3K) inhibitor	B. Kinase inhibitor	Investigational (Ph 2)	DMSO	1000
5	Cladribine	Antimetabolite; Purine analog	A. Conv. Chemo	Approved	DMSO	1000
6	Idarubicin	Topoisomerase II inhibitor	A. Conv. Chemo	Approved	DMSO	1000
7	Panobinostat	HDAC inhibitor	E. Differentiating/epigenetic modifier	Approved	DMSO	1000
8	Clofarabine	Antimetabolite; Purine analog	A. Conv. Chemo	Approved	DMSO	
9	Fludarabine	Antimetabolite; Purine analog	A. Conv. Chemo	Approved	DMSO	10000
10	Vorinostat	HDAC inhibitor	E. Differentiating/epigenetic modifier	Approved	DMSO	10000
11	Bortezomib	Proteasome inhibitor (26S subunit)	L. Protease/proteasome inhibitor	Approved	DMSO	
12	Tipifarnib	Farnesyltransferase inhibitor	E. Differentiating/epigenetic modifier	Investigational (Ph 3)	DMSO	10000
13	Ponatinib	Broad TK inhibitor	B. Kinase inhibitor	Approved	DMSO	1000
14	Cytarabine	Antimetabolite, interferes with DNA synthesis	A. Conv. Chemo	Approved	DMSO	
15	Carfilzomib	Proteasome inhibitor (20S subunit)	L. Protease/proteasome inhibitor	Approved	DMSO	1000
16	Etoposide	Topoisomerase II inhibitor	A. Conv. Chemo	Approved	DMSO	10000
17	Idelalisib	PI3K inhibitor, p110 γ -selective	B. Kinase inhibitor	Approved	DMSO	10000
18	Palbociclib	CDK4/6 inhibitor	B. Kinase inhibitor	Approved	AQ	10000
19	Mitoxantrone	Topoisomerase II inhibitor	A. Conv. Chemo	Approved	DMSO	1000
20	Ruxolitinib	JAK1&2 inhibitor	B. Kinase inhibitor	Approved	DMSO	10000
21	Topotecan	Topoisomerase I inhibitor. Camptothecin analog	A. Conv. Chemo	Approved	DMSO	10000
22	Canertinib	pan-HER inhibitor	B. Kinase inhibitor	Investigational (Ph 3)	DMSO	10000
23	Valrubicin	Topoisomerase II inhibitor	A. Conv. Chemo	Approved	DMSO	5000
24	Vincristine	Mitotic inhibitor. Vinca alkaloid	A. Conv. Chemo	Approved	DMSO	1000

		microtubule depolymerizer				
25	Dactinomycin	RNA and DNA synthesis inhibitor	A. Conv. Chemo	Approved	DMSO	1000
26	Daunorubicin	Topoisomerase II inhibitor	A. Conv. Chemo	Approved	DMSO	1000
27	Doxorubicin	Topoisomerase II inhibitor	A. Conv. Chemo	Approved	DMSO	1000
28	Entinostat	HDAC inhibitor	E. Differentiating/epigenetic modifier	Investigational (Ph 2)	DMSO	10000
29	Luminespib	HSP90 inhibitor	K. HSP inhibitor	Investigational (Ph 2)	DMSO	1000
30	Fingolimod	S1PR antagonist	X. Other	Approved	DMSO	10000
31	Sepantronium bromide	Survivin inhibitor	G. Apoptotic modulator	Investigational (Ph 2)	DMSO	10000
32	Azacitidine	Nucleoside analog DNA methyl transferase inhibitor	E. Differentiating/epigenetic modifier	Approved	DMSO	10000
33	BI 2536	PLK1 inhibitor	B. Kinase inhibitor	Investigational (Ph 2)	DMSO	1000
34	Masitinib	KIT inhibitor	B. Kinase inhibitor	Investigational (Ph 3)	DMSO	10000
35	Omacetaxine	Protein synthesis inhib (80 S ribosome)	A. Conv. Chemo	Approved	DMSO	10000
36	Pictilisib	PI3K inhibitor, pan-class I	B. Kinase inhibitor	Investigational (Ph 2)	DMSO	10000
37	Alisertib	Aurora A inhibitor	B. Kinase inhibitor	Investigational (Ph 3)	DMSO	10000
38	Erlotinib	EGFR inhibitor	B. Kinase inhibitor	Approved	DMSO	10000
39	Plicamycin	RNA synthesis inhibitor	A. Conv. Chemo	Approved	DMSO	
40	Vinorelbine	Mitotic inhibitor. Vinca alkaloid microtubule depolymerizer	A. Conv. Chemo	Approved	DMSO	
41	Gefitinib	EGFR inhibitor	B. Kinase inhibitor	Approved	DMSO	10000
42	Regorafenib	B-Raf, c-Kit, VEGFR2 inhibitor	B. Kinase inhibitor	Approved	DMSO	10000
43	Trametinib	MEK1/2 inhibitor	B. Kinase inhibitor	Approved	DMSO	250
44	ABT-751	Mitotic inhibitor. Colchicine site binding microtubule depolymerizer.	A. Conv. Chemo	Investigational (Ph 2)	DMSO	10000
45	AZD1775	Wee1 inhibitor	B. Kinase inhibitor	Investigational (Ph 2)	DMSO	10000
46	Gemcitabine	Antimetabolite; Nucleoside analog	A. Conv. Chemo	Approved	DMSO	1000
47	Alvocidib	CDK inhibitor	B. Kinase inhibitor	Investigational (Ph 2)	DMSO	10000

Supplementary Table 3: SNPs showing sub-exome wide significance ($p < 10^{-4}$) level association with ex-vivo response of drugs in the single variant analysis.

SN	chr	POS	SNP	Gene	A1/A2	N	BETA	SE	P	Drug
1	16	89940166	rs139741086	TCF25	G/T	174	10.24	2.0173	1.01x10-06	Ruxolitinib
2	5	7743787	rs62342477	ADCY2	T/C	175	3.89	0.77363	1.25 x10-06	Sepantronium
3	6	36343721	rs2234075	ETV7	G/A	174	-9.01	1.81208	1.64 x10-06	Belinostat
4	5	150646888	rs61740602	GM2A	T/C	175	6.62	1.33453	1.71 x10-06	Alvocidib
5	17	3486702	rs224534	TRPV1	G/A	175	-2.11	0.430525	2.20 x10-06	Belinostat
6	6	29069264	rs2394516	OR2J1	C/T	175	-2.07	0.422287	2.33 x10-06	Cladribine
7	6	29069299	rs2394517	OR2J1	T/C	175	-2.07	0.422287	2.33 x10-06	Cladribine
8	6	29069016	rs3131088	OR2J1	A/G	175	-2.07	0.422287	2.33 x10-06	Cladribine
9	3	63981635	rs3733125	ATXN7	C/T	175	3.49	0.718057	2.60 x10-06	Cytarabine
10	19	1924189	rs75734024	SCAMP4	C/T	174	-9.92	2.04163	2.70 x10-06	Panobinostat
11	11	124267148	rs77374761	OR8B3	C/T	175	-1.59	0.330076	3.18 x10-06	ABT 751
12	1	9780836	rs201274224	PIK3CD	T/G	174	-5.01	1.0416	3.30 x10-06	Daunorubicin
13	5	140188709	rs147674000	PCDHA1	G/T	173	15.09	3.13424	3.31 x10-06	Vincristine
14	16	89764357	rs150653847	SPATA2L	A/G	173	9.64	2.02419	4.14 x1006	Ruxolitinib
15	16	89790059	rs4516230	ZNF276	G/A	172	9.63	2.03091	4.52 x10-06	Ruxolitinib
16	21	32639157	rs142183230	TIAM1	C/T	174	6.23	1.31629	4.64 x10-06	Azacitidine
17	19	43702335	rs140068216	PSG4	C/G	173	3.64	0.770511	4.90 x10-06	Tamoxifen
18	6	29069264	rs2394516	OR2J1	C/T	175	-2.72	0.577966	5.08 x10-06	Cladribine
19	6	29069299	rs2394517	OR2J1	T/C	175	-2.72	0.577966	5.08 x10-06	Cladribine
20	6	29069016	rs3131088	OR2J1	A/G	175	-2.72	0.577966	5.08 x10-06	Cladribine
21	19	52658231	rs61744685	ZNF836	C/T	175	4.20	0.903054	6.71 x10-06	Azacitidine
22	3	50144951	rs1061474	RBM5	C/T	175	-3.91	0.843793	7.02 x10-06	Sepantronium
23	2	42515437	rs28651764	EML4	A/G	175	-2.09	0.451982	7.30 x10-06	Cladribine
24	4	85414643	rs147737825	NKX6-1	C/T	175	12.78	2.76872	7.35 x10-06	Trametinib

25	9	85863091	rs10114696	FRMD3	A/G	175	2.79	0.60249	7.43 x10-06	Entinostat
26	17	45219299	rs113472284	CDC27	G/A	175	3.36	0.731188	8.468 x10-06	Mitoxantrone
27	3	128627887	rs4494951	ACAD9	G/A	175	5.04	1.1008	8.86 x10-06	Mitoxantrone
28	2	26537317	rs150700942	GPR113	T/C	175	6.38	1.39257	9.02 x10-06	Dactolisib
29	1	94343233	rs3789457	DNTTIP2	C/T	175	1.68	0.366324	9.10 x10-06	ABT 751
30	10	3172121	rs1052333	PFKP	C/T	175	-3.13	0.68556	9.16 x10-06	Canertinib
31	18	77246527	rs200207441	NFATC1	C/T	174	-5.97	1.30571	9.37 x10-06	Regorafenib
32	10	72015409	rs10999212	NPPFR1	C/A	173	1.44	0.315264	9.49 x10-06	Canertinib
33	18	50976898	rs35891220	DCC	G/A	175	9.49	2.07884	9.77 x10-06	Ruxolitinib
34	17	3486702	rs224534	TRPV1	G/A	175	-1.97	0.431822	1.02 x10-05	Belinostat
35	17	61607708	rs7221517	KCNH6	T/C	175	-1.70	0.374366	1.04 x10-05	ABT 751
36	5	150646888	rs61740602	GM2A	T/C	175	4.63	1.01862	1.05 x10-05	Alvocidib
37	2	182981968	rs1882212	PPP1R1C	A/G	175	-2.94	0.650471	1.17 x10-05	Erlotinib
38	16	4519439	rs11557236	NMRAL1	G/A	175	-5.21	1.1526	1.17 x10-05	Topotecan
39	5	140255271	rs17844351	PCDHA1	G/C	175	12.50	2.76872	1.18 x10-05	Vincristine
40	12	88481632	rs117122459	CEP290	T/C	175	-4.60	1.01985	1.22 x10-05	Vorinostat
41	10	102676996	rs41291454	FAM178A	C/T	175	10.38	2.30431	1.24 x10-05	Ruxolitinib
42	2	179203797	rs1434087	OSBPL6	A/G	175	-4.73	1.04991	1.25 x10-05	Alisertib
43	14	39777676	rs1950952	MIA2	C/G	175	-1.23	0.273735	1.26 x10-05	Gefitinib
44	1	10473200	rs41289075	PGD	G/A	175	2.83	0.631945	1.39 x10-05	Gefitinib
45	3	56330063	rs75898504	ERC2	T/A	175	11.50	2.56859	1.40 x10-05	Trametinib
46	10	3172121	rs1052333	PFKP	C/T	175	-2.88	0.644659	1.412 x10-05	Canertinib
47	19	56320663	rs12461110	NLRP11	G/A	175	2.04	0.457903	1.44 x10-05	Cladribine
48	11	10655609	rs2162044	MRVI1	T/C	175	5.11	1.14473	1.45 x10-05	ABT 751
49	1	158369064	rs41488350	OR10T2	A/G	175	4.24	0.951004	1.51 x10-05	AZD1775
50	1	158368964	rs61818749	OR10T2	C/T	175	4.24	0.951004	1.51 x10-05	AZD1775
51	1	158368974	rs61818750	OR10T2	A/G	175	4.24	0.951004	1.51 x10-05	AZD1775
52	3	50114515	rs7061	RBM6	T/C	175	-3.80	0.856393	1.60 x10-05	Sepantronium
53	19	57058998	rs34136271	ZFP28	C/G	175	4.31	0.972371	1.64 x10-05	Trametinib

54	1	9780836	rs201274224	PIK3CD	T/G	174	-8.47	1.90938	1.64 x10-05	Daunorubicin
55	6	36343721	rs2234075	ETV7	G/A	174	-8.10	1.82689	1.68 x10-05	Belinostat
56	11	5629607	rs10769121	TRIM6	G/A	175	2.08	0.469568	1.71 x10-05	Bortezomib
57	1	159897638	rs77570237	IGSF9	T/C	175	10.43	2.35773	1.74 x10-05	Ruxolitinib
58	6	160670282	rs316019	SLC22A2	C/A	175	-3.19	0.723093	1.77 x10-05	Masitinib
59	13	111335406	rs146773721	CARS2	C/T	175	-5.96	1.34991	1.83 x10-05	Daunorubicin
60	19	51132746	rs61746970	SYT3	G/A	175	6.82	1.55013	1.89 x10-05	Omacetaxine
61	6	31323321	rs1050723	HLA-B	G/A	175	-4.49	1.02017	1.91 x10-05	Dactolisib
62	1	23418803	rs35645814	LUZP1	G/C	175	10.60	2.41219	1.94 x10-05	Clofarabine
63	1	12082334	rs11553925	MIIP	A/T	174	1.05	0.239787	1.94 x10-05	Fingolimod
64	7	134618496	rs61757650	CALD1	G/A	175	7.44	1.69289	1.95 x10-05	Clofarabine
65	4	44176960	rs13143747	KCTD8	T/C	175	-3.52	0.801503	1.97 x10-05	Daunorubicin
66	19	57036678	rs3752177	ZNF471	G/A	175	4.15	0.944841	1.97 x10-05	Trametinib
67	7	101892229	rs149171097	CUX1	C/A	172	3.51	0.801913	2.10 x10-05	Azacitidine
68	3	50153356	rs1138536	RBM5	C/T	175	-3.69	0.843071	2.13 x10-05	Sepantronium
69	2	20494189	rs34032508	PUM2	T/C	175	8.49	1.94851	2.13 x10-05	Ruxolitinib
70	17	78176044	rs117918077	CARD14	C/T	175	8.93	2.05308	2.34 x10-05	BI 2536
71	21	46927489	rs12483761	COL18A1	A/G	175	3.49	0.804165	2.37 x10-05	Palbociclib
72	7	151962265	rs201834857	MLL3	C/T	175	-4.49	1.0323	2.37 x10-05	Idarubicin
73	13	27250823	rs3764108	WASF3	T/C	175	3.27	0.751919	2.38 x10-05	Tipifarnib
74	17	56386732	rs61741210	BZRAP1	C/T	175	-4.27	0.981987	2.42 x10-05	Palbociclib
75	17	56405046	rs61743284	BZRAP1	C/T	175	-4.27	0.981987	2.42 x10-05	Palbociclib
76	8	25174616	rs142262406	DOCK5	C/G	175	13.09	3.01538	2.44 x10-05	Ruxolitinib
77	1	53676448	rs1799821	CPT2	A/G	175	1.45	0.333593	2.44 x10-05	Canertinib
78	1	156255456	rs6684514	TMEM79	G/A	174	3.42	0.788271	2.44 x10-05	Luminespib
79	3	40251392	rs1799418	MYRIP	C/T	175	2.92	0.67321	2.48 x10-05	Omacetaxine
80	3	128758556	rs75140996	CCDC48	G/C	173	4.80	1.10791	2.51 x10-05	Mitoxantrone
81	2	85826721	rs11891495	TMEM150A	G/A	175	2.79	0.645287	2.55 x10-05	Dactinomycin
82	12	104100617	rs697212	STAB2	T/C	175	2.17	0.501237	2.59 x10-05	Gemcitabine

83	14	24035079	rs140983547	AP1G2	C/T	175	3.84	0.887515	2.60 x10-05	Alvocidib
84	20	62642781	rs111366685	ZNF512B	G/A	175	8.17	1.88939	2.630 x10-05	Trametinib
85	2	182981968	rs1882212	PPP1R1C	A/G	175	-1.66	0.384976	2.64 x10-05	Erlotinib
86	5	150908812	rs7718054	FAT2	C/T	175	2.75	0.636429	2.64 x10-05	Azacitidine
87	9	73233933	rs139079542	TRPM3	C/T	175	12.49	2.89132	2.65 x10-05	Trametinib
88	7	151962265	rs201834857	MLL3	C/T	175	-1.49	0.346761	2.66 x10-05	Idarubicin
89	2	179644035	rs1552280	TTN	A/G	175	-5.54	1.28301	2.67 x10-05	Alisertib
90	12	120954490	rs3742049	COQ5	C/T	175	3.68	0.852935	2. x10-05	Idarubicin
91	1	1960674	rs28408173	GABRD	C/T	174	3.51	0.814041	2.71 x10-05	Ruxolitinib
92	19	55144147	rs74906426	LILRB1	C/T	172	6.18	1.43689	2.86 x10-05	Mitoxantrone
93	17	34328461	rs854625	CCL14	G/A	175	-2.83	0.658233	2.91 x10-05	Bortezomib
94	4	110772711	rs17040904	LRIT3	C/T	175	4.11	0.957853	3.03 x10-05	Dactinomycin
95	12	11286249	rs77777159	TAS2R30	T/C	175	3.29	0.76965	3.06 x10-05	Vorinostat
96	1	55352613	rs79857573	DHCR24	G/A	175	7.82	1.82689	3.08 x10-05	Dactolisib
97	21	32493031	rs762194	TIAM1	G/A	175	-3.03	0.707884	3.14 x10-05	Topotecan
98	18	55335366	rs28424873	ATP8B1	G/T	175	-3.04	0.71231	3.16 x10-05	Belinostat
99	3	57431945	rs62622492	DNAH12	T/C	175	-5.93	0.70	3.19 x10-05	Doxorubicin
100	22	19470249	rs13447203	CDC45	G/A	175	5.42	1.26736	3.21 x10-05	Canertinib
101	1	41300682	rs55925184	KCNQ4	C/T	175	-4.33	1.01397	3.23 x10-05	Panobinostat
102	5	5190182	rs34105281	ADAMTS16	C/T	175	11.03	2.58438	3.26 x10-05	Trametinib
103	6	157743741	rs187769654	TMEM242	T/C	175	9.24	2.1639	3.27 x10-05	Ruxolitinib
104	3	57139972	rs1545981	IL17RD	G/A	175	5.26	1.23406	3.30 x10-05	Luminespib
105	10	75533448	rs3740289	FUT11	A/G	175	7.36	1.72594	3.30 x10-05	Alisertib
106	20	33665969	rs139800499	TRPC4AP	C/T	175	14.07	3.29915	3.34 x10-05	Luminespib
107	2	69709919	rs6721259	AAK1	A/G	175	3.78	0.886825	3.34 x10-05	Vincristine
108	20	62597694	rs817329	ZNF512B	G/T	175	-3.69	0.868033	3.41 x10-05	Plicamycin
109	2	79313990	rs62640882	REG1B	C/T	175	-4.17	0.980084	3.45 x10-05	Vorinostat
110	11	61089771	rs28720291	DDB1	C/T	175	-9.52	2.23507	3.45 x10-05	Etoposide
111	11	10655609	rs2162044	MRVI1	T/C	175	9.22	2.16944	3.53 x10-05	ABT 751

112	22	29446695	rs55962108	ZNRF3	G/A	174	5.01	1.18063	3.67 x10-05	Alisertib
113	14	68045935	rs6573781	PLEKHH1	A/G	174	4.48	1.05644	3.68 x10-05	Vinorelbine
114	17	34340284	rs1003645	CCL23	T/C	175	-2.13	0.503314	3.68 x10-05	Bortezomib
115	5	71756670	rs2278600	ZNF366	C/T	174	1.28	0.302691	3.74 x10-05	Fingolimod
116	22	36684980	rs11549907	MYH9	G/A	174	8.79	2.07817	3.79 x10-05	Dactinomycin
117	11	71259822	rs10792769	KRTAP5-9	A/G	172	-1.97	0.465157	3.84 x10-05	Fludarabine
118	5	153783753	rs6580076	GALNT10	C/T	174	3.57	0.845073	3.84 x10-05	BI 2536
119	12	57004268	rs34393899	BAZ2A	G/A	175	-6.64	1.57047	3.85 x10-05	Sepantronium
120	1	10342522	rs17034660	KIF1B	G/A	175	2.62	0.618812	3.88 x10-05	Gefitinib
121	1	10397567	rs2297881	KIF1B	A/G	175	2.62	0.618812	3.88 x10-05	Gefitinib
122	1	205385412	rs16855539	LEMD1	A/G	172	6.26	1.48127	3.90 x10-05	Alisertib
123	1	160650938	rs6667145	CD48	C/T	175	3.04	0.720689	3.93 x10-05	Idelalisib
124	13	111335406	rs146773721	CARS2	C/T	175	-5.26	1.24575	3.96 x10-05	Daunorubicin
125	10	3172121	rs1052333	PFKP	C/T	175	-2.06	0.489569	3.96 x10-05	Canertinib
126	22	24300540	rs144128236	GSTT2B	C/T	173	8.46	2.00479	4.03 x10-05	Erlotinib
127	19	55346534	rs112522228	KIR3DL1	G/C	172	-2.70	0.639847	4.04 x10-05	Cladribine
128	22	36691691	rs875725	MYH9	T/C	175	8.76	2.07803	4.08 x10-05	Dactinomycin
129	1	42896441	rs41301052	ZMYND12	C/A	175	7.23	1.71615	4.08 x10-05	Luminespib
130	1	9780836	rs201274224	PIK3CD	T/G	174	-8.67	2.05703	4.08 x10-05	Daunorubicin
131	2	219221846	rs4324314	C2orf62	G/A	175	-2.96	0.702267	4.08 x10-05	Dactinomycin
132	4	9922170	rs73225891	SLC2A9	C/G	175	-4.62	1.09711	4.15 x10-05	Mitoxantrone
133	1	9780836	rs201274224	PIK3CD	T/G	174	-4.39	1.04434	4.16 x10-05	Daunorubicin
134	14	24035079	rs140983547	AP1G2	C/T	175	6.27	1.48923	4.19 x10-05	Alvocidib
135	10	3172121	rs1052333	PFKP	C/T	175	-1.33	0.316233	4.20 x10-05	Canertinib
136	22	29446695	rs55962108	ZNRF3	G/A	174	5.28	1.25589	4.22 x10-05	Alisertib
137	6	149700491	rs3734296	TAB2	G/A	175	4.05	0.964672	4.34 x10-05	Vincristine
138	6	149730846	rs652921	TAB2	G/A	175	4.05	0.964672	4.34 x10-05	Vincristine
139	20	62595169	rs817325	ZNF512B	G/A	174	-3.67	0.875653	4.38 x10-05	Plicamycin
140	1	156264000	rs10908496	C1orf85	G/A	175	3.29	0.786347	4.42 x10-05	Luminespib

141	3	57431945	rs62622492	DNAH12	T/C	175	-2.96	0.706064	4.43 x10-05	Doxorubicin
142	20	30915461	rs1129012	KIF3B	T/C	175	-1.23	0.293314	4.44 x10-05	Fingolimod
143	1	211652382	rs143207434	RD3	T/A	174	9.78	2.33347	4.46 x10-05	Ruxolitinib
144	3	128634037	rs113633667	ACAD9	C/T	173	4.66	1.11312	4.48 x10-05	Mitoxantrone
145	14	94103602	rs4905082	UNC79	A/G	175	1.91	0.456456	4.49 x10-05	Alvocidib
146	16	16139714	rs35587	ABCC1	T/C	175	1.60	0.382435	4.61 x10-05	Carfilzomib
147	6	35426175	rs3823434	FANCE	C/T	175	-4.87	1.16443	4.61 x10-05	Gemcitabine
148	2	27438615	rs11556165	C2orf28	G/C	175	4.42	1.05619	4.64 x10-05	Belinostat
149	1	39340862	rs874243	MYCBP	A/G	175	-2.17	0.518982	4.66 x10-05	Daunorubicin
150	15	85341859	rs8182086	ZNF592	G/A	175	1.89	0.452726	4.76 x10-05	ABT 751
151	1	42630364	rs2071499	GUCA2A	A/G	173	-1.63	0.391391	4.76 x10-05	Carfilzomib
152	14	94103602	rs4905082	UNC79	A/G	175	3.06	0.734085	4.82 x10-05	Alvocidib
153	10	13378273	rs62641683	SEPHS1	G/C	175	-6.72	1.61033	4.85 x10-05	Gemcitabine
154	19	49898404	rs191973091	CCDC155	G/A	174	3.28	0.78707	4.86 x10-05	Fingolimod
155	1	10479791	rs41274480	PGD	G/A	175	2.73	0.656193	4.91 x10-05	Gefitinib
156	5	140362125	rs79247475	PCDHA1	C/G	175	8.74	2.09841	4.97 x10-05	Luminespib
157	17	3844787	rs1800912	ATP2A3	C/G	173	-4.07	0.977207	4.99 x10-05	Plicamycin
158	2	96798440	rs61735195	ASTL	C/T	175	4.38	1.0511	0.000050169	Fludarabine
159	22	43289473	rs5759013	PACSIN2	G/A	174	-2.01	0.481869	5.02 x10-05	Alisertib
160	7	151962257	rs62478357	MLL3	C/T	175	-1.45	0.347914	5.04 x10-05	Idarubicin
161	1	114438951	rs1217401	AP4B1	A/G	175	1.99	0.478235	5.05 x10-05	Cladribine
162	17	78176044	rs117918077	CARD14	C/T	175	9.55	2.29659	5.06 x10-05	BI 2536
163	18	55335366	rs28424873	ATP8B1	G/T	175	-3.28	0.788452	5.10 x10-05	Belinostat
164	11	117335686	rs61743159	DSCAML1	G/A	175	5.48	1.31703	5.13 x10-05	Clofarabine
165	14	94103602	rs4905082	UNC79	A/G	175	2.03	0.489657	5.23 x10-05	Alvocidib
166	22	24300540	rs144128236	GSTT2B	C/T	173	4.97	1.19807	5.23 x10-05	Erlotinib
167	2	173352157	rs2293648	ITGA6	A/T	175	-5.93	1.42929	5.25 x10-05	BI 2536
168	6	28963248	rs6456880	ZNF311	T/G	175	-1.79	0.432058	5.31 x10-05	Cladribine
169	16	1260969	rs61910714	CACNA1H	G/A	174	-3.72	0.897501	5.34 x10-05	Alisertib

170	19	17366278	rs4430871	USHBP1	C/T	173	-2.19	0.530052	5.42 x10-05	Alisertib
171	11	124267148	rs77374761	OR8B3	C/T	175	-1.75	0.421865	5.43 x10-05	ABT 751
172	2	42515437	rs28651764	EML4	A/G	175	-1.50	0.36251	5.46 x10-05	Cladribine
173	5	150646888	rs61740602	GM2A	T/C	175	3.00	0.724778	5.48 x10-05	Alvocidib
174	10	14890829	rs45567440	HSPA14	C/A	175	-8.49	2.05034	5.51 x10-05	Belinostat
175	1	41012847	rs41268081	ZNF684	A/G	175	3.28	0.792814	5.54 x10-05	Masitinib
176	X	12904662	rs5743780	TLR7	G/A	175	7.42	1.79282	5.56 x10-05	Clofarabine
177	21	32639157	rs142183230	TIAM1	C/T	174	9.25	1.31	5.62 x10-05	Azacitidine
178	5	79026187	rs17253860	CMYA5	A/G	175	-7.00	1.69362	5.62 x10-05	Carfilzomib
179	12	27064232	rs3210635	ASUN	T/C	175	-2.52	0.609084	5.66 x10-05	ABT 751
180	1	17660499	rs874881	PADI4	C/G	175	1.57	0.382264	5.69 x10-05	ABT 751
181	16	84228873	rs11865115	ADAD2	C/T	174	-2.47	0.598834	5.73 x10-05	Daunorubicin
182	1	215901492	rs2820718	USH2A	C/T	175	-1.23	0.297314	5.73 x10-05	Gefitinib
183	5	115811273	rs17432496	CTB-118N6.3	C/T	175	5.43	1.31591	5.74 x10-05	Regorafenib
184	1	156263940	rs10908495	C1orf85	T/C	175	3.24	0.785168	5.74 x10-05	Luminespib
185	18	55322502	rs12968116	ATP8B1	C/T	175	3.69	0.89294	5.79 x10-05	AZD1775
186	22	32111553	rs140450525	PRR14L	G/A	175	3.27	0.793453	5.79 x10-05	Gefitinib
187	1	89449218	rs113402009	CCBL2	G/A	175	-9.68	2.34926	5.92 x10-05	Mitoxantrone
188	1	53980367	rs142735388	GLIS1	G/A	174	5.52	1.34	6.02 x10-05	Azacitidine
189	10	75533448	rs3740289	FUT11	A/G	175	6.70	1.62832	6.06 x10-05	Alisertib
190	4	139140494	rs6838248	SLC7A11	G/C	175	2.08	0.506795	6.06 x10-05	Vorinostat
191	21	46927489	rs12483761	COL18A1	A/G	175	1.79	0.434703	6.171 x10-05	Palbociclib
192	2	69709919	rs6721259	AAK1	A/G	175	4.55	1.10851	6.23 x10-05	Vincristine
193	14	94187832	rs1887197	PRIMA1	T/C	175	1.83	0.44549	6.23 x10-05	Panobinostat
194	19	53117809	rs10406458	ZNF83	A/C	175	3.08	0.750271	6.23 x10-05	Tipifarnib
195	12	57861785	rs61734545	GLI1	T/C	175	-7.67	1.86829	6.26 x10-05	Sepantronium
196	13	42876290	rs41288311	AKAP11	A/C	175	2.37	0.576452	6.33 x10-05	Belinostat
197	22	24300540	rs144128236	GSTT2B	C/T	173	4.28	1.0437	6.35 x10-05	Erlotinib
198	5	73090261	rs7716253	ARHGFE28	C/T	175	2.19	0.534259	6.37 x10-05	Gemcitabine

199	2	132021078	rs200735283	PLEKHB2	A/G	172	6.24	1.52167	6.39 x10-05	Idelalisib
200	19	58992029	rs142233722	ZNF446	G/A	172	12.53	3.05669	6.46 x10-05	Ruxolitinib
201	15	100211780	rs201205600	MEF2A	A/G	175	13.48	3.28875	6.49 x10-05	Luminespib
202	15	91496242	rs8041035	AC068831.6	C/T	175	4.62	1.12803	6.50 x10-05	Cladribine
203	10	50667120	rs61760167	ERCC6	T/G	175	12.12	2.95843	6.51 x10-05	BI 2536
204	2	166781158	rs2163649	TTC21B	G/A	175	2.22	0.542945	6.54 x10-05	Tamoxifen
205	2	166767913	rs80225158	TTC21B	C/G	175	2.22	0.542945	6.54 x10-05	Tamoxifen
206	2	136546110	rs2278544	LCT	G/A	175	-2.27	0.554641	6.57 x10-05	Idelalisib
207	8	18080196	rs4986783	NAT1	T/G	175	3.17	0.773925	6.57 x10-05	Tamoxifen
208	8	18080015	rs4986990	NAT1	G/A	175	3.17	0.773925	6.57 x10-05	Tamoxifen
209	8	18080001	rs4987076	NAT1	G/A	175	3.17	0.773925	6.57 x10-05	Tamoxifen
210	1	152692512	rs41268474	C1orf68	G/A	175	-2.08	0.508526	6.69 x10-05	Azacitidine
211	19	37039069	rs2912444	ZNF529	C/A	175	-2.06	0.504192	6.79 x10-05	Cladribine
212	6	36343721	rs2234075	ETV7	G/A	174	-10.73	2.62717	6.84 x10-05	Belinostat
213	22	43203137	rs738535	ARFGAP3	C/T	175	-1.98	0.484845	6.90 x10-05	Regorafenib
214	12	46589988	rs11608815	SLC38A1	C/T	174	4.89	1.19763	6.99 x10-05	Sepantronium
215	1	9780836	rs201274224	PIK3CD	T/G	174	-8.64	2.11911	7.00 x10-05	Daunorubicin
216	1	9780836	rs201274224	PIK3CD	T/G	174	-5.64	1.38236	7.00 x10-05	Daunorubicin
217	7	87138645	rs1045642	ABCB1	A/G	175	2.41	0.592489	7.04 x10-05	Entinostat
218	22	32234797	rs61731664	DEPDC5	G/A	175	3.08	0.755554	7.06 x10-05	Gefitinib
219	22	32200161	rs79070552	DEPDC5	T/C	175	3.08	0.755554	7.06 x10-05	Gefitinib
220	7	150765065	rs2229550	SLC4A2	C/T	174	-3.85	0.944492	7.13 x10-05	Omacetaxine
221	9	140147765	rs1134511	C9orf173	C/T	173	6.35	1.55913	7.13 x10-05	Entinostat
222	12	27064232	rs3210635	ASUN	T/C	175	-1.53	0.37667	7.14 x10-05	ABT 751
223	16	79245687	rs199576434	WWOX	C/T	174	-8.46	2.07766	7.18 x10-05	Belinostat
224	6	26285683	rs2393593	HIST1H4H	C/T	175	2.23	0.545008	7.23 x10-05	Dactinomycin
225	18	61600384	rs963075	SERPINB10	C/T	175	2.87	0.706917	7.30 x10-05	Idarubicin
226	7	87179601	rs1128503	ABCB1	G/A	175	-1.76	0.434256	7.37 x10-05	Cladribine
227	5	73931246	rs442425	ENC1	C/T	175	-1.09	0.268149	7.39 x10-05	Gefitinib

228	1	42896441	rs41301052	ZMYND12	C/A	175	7.59	1.86918	7.39 x10-05	Luminespib
229	11	1018169	rs77647814	MUC6	C/G	175	4.20	1.05773	7.41 x10-05	Vorinostat
230	11	72408055	rs56200889	ARAP1	G/C	173	1.64	0.404591	7.43 x10-05	Bortezomib
231	7	142655008	rs8176058	KEL	G/A	175	-6.64	1.63483	7.49 x10-05	Panobinostat
232	5	35072712	rs72478580	PRLR	T/G	175	-6.44	1.59	7.55 x10-05	Masitinib
233	6	111628626	rs3204953	REV3L	C/T	175	3.35	0.826582	7.60 x10-05	Dactinomycin
234	6	111628597	rs3204954	REV3L	C/G	175	3.35	0.826582	7.60 x10-05	Dactinomycin
235	1	53980367	rs142735388	GLIS1	G/A	174	8.37	2.06582	7.71 x10-05	Azacitidine
236	2	26676349	rs200824609	CCDC164	C/G	175	12.34	3.04501	7.72 x10-05	Ruxolitinib
237	7	150695726	rs1549758	NOS3	C/T	173	-2.09	0.516395	7.75 x10-05	Dactolisib
238	10	102738766	rs118166648	MRPL43	T/C	175	-2.54	0.628189	7.83 x10-05	ABT 751
239	16	111247	rs79691782	RHBDF1	C/T	173	-5.34	1.31978	7.99 x10-05	Omacetaxine
240	5	64887614	rs61748229	TRIM23	T/C	175	-6.81	1.68432	8.08 x10-05	Trametinib
241	2	69741801	rs6757825	AAK1	C/T	175	4.53	1.12155	8.11 x10-05	Vinorelbine
242	2	135745129	rs16831235	YSK4	G/A	175	-1.47	0.364262	8.12 x10-05	Gefitinib
243	17	7484782	rs17607	CD68	G/A	175	-2.17	0.536206	8.14 x10-05	Azacitidine
244	22	43289473	rs5759013	PACSIN2	G/A	174	-2.14	0.529237	8.19 x10-05	Alisertib
245	17	45219299	rs113472284	CDC27	G/A	175	3.61	0.895523	8.25 x10-05	Mitoxantrone
246	4	120240238	rs1511025	FABP2	T/C	175	1.49	0.370131	8.32 x10-05	Palbociclib
247	17	76045806	rs141190761	TNRC6C	C/T	175	-8.33	2.06506	8.35 x10-05	Panobinostat
248	20	60768573	rs41284984	GTPBP5	C/T	175	7.64	1.89595	8.37 x10-05	Tipifarnib
249	7	101892229	rs149171097	CUX1	C/A	172	5.40	1.33925	8.43 x10-05	Azacitidine
250	22	38328597	rs34834842	MICALL1	A/G	175	-5.91	1.46645	8.44 x10-05	Regorafenib
251	6	152772264	rs214976	SYNE1	A/G	175	-2.41	0.597412	8.44 x10-05	Entinostat
252	14	68035879	rs3825725	PLEKHH1	A/G	175	-2.57	0.63857	8.51 x10-05	Mitoxantrone
253	6	169064783	rs118133242	SMOC2	A/G	175	9.79	2.43404	8.69 x10-05	Entinostat
254	11	2924591	rs1048046	SLC22A18AS	G/A	174	-1.91	0.474677	8.7192 x10-05	Panobinostat
255	6	159457826	rs144047559	TAGAP	C/G	175	8.29	2.06417	8.787 x10-05	Idelalisib
256	3	40286017	rs4618168	MYRIP	T/C	175	2.68	0.666225	8.82 x10-05	Omacetaxine

257	4	118975146	rs13152576	NDST3	C/T	175	3.02	0.751172	8.84 x10-05	AZD1775
258	20	60791866	rs41284986	HRH3	G/A	175	-8.85	2.20105	8.84 x10-05	Clofarabine
259	17	3476990	rs17706245	TRPV1	G/A	175	-4.58	1.14075	8.89 x10-05	Masitinib
260	17	3480910	rs34378673	TRPV1	A/G	175	-4.58	1.14075	8.89 x10-05	Masitinib
261	17	3475490	rs877610	TRPV1	C/T	175	-4.58	1.14075	8.89 x10-05	Masitinib
262	3	4856180	rs711631	AC018816.3	C/T	175	3.76	0.937373	8.96 x10-05	Masitinib
263	5	78340257	rs248385	DMGDH	C/G	175	-1.93	0.480411	8.96 x10-05	Dactolisib
264	5	78340286	rs532964	DMGDH	A/G	175	-1.93	0.480411	8.96 x10-05	Dactolisib
265	6	26033641	rs2230654	HIST1H2AB	G/A	174	-4.86	1.21046	8.99 x10-05	Vinorelbine
266	2	85824039	rs1127974	RNF181	G/A	175	2.92	0.728904	8.99 x10-05	Dactinomycin
267	3	4856180	rs711631	AC018816.3	C/T	175	2.41	0.600483	9.05 x10-05	Masitinib
268	18	55335366	rs28424873	ATP8B1	G/T	175	-2.23	0.557855	9.06 x10-05	Belinostat
269	1	152538495	rs141660085	LCE3E	G/A	174	4.34	1.08302	9.09 x10-05	Erlotinib
270	1	53600078	rs3737989	SLC1A7	A/G	175	3.30	0.824444	9.11 x10-05	Clofarabine
271	1	22154845	rs2228347	HSPG2	A/G	175	-3.77	0.939706	9.21 x10-05	Navitoclax
272	22	38470909	rs200682835	PICK1	A/T	175	10.16	2.53611	9.22 x10-05	Dactinomycin
273	1	228871693	rs3738073	RHOU	C/T	173	-1.83	0.457717	9.22 x10-05	Doxorubicin
274	11	60102507	rs2304933	MS4A6E	T/G	175	2.27	0.566338	9.26 x10-05	BI 2536
275	11	60102396	rs2304934	MS4A6E	G/A	175	2.27	0.566338	9.26 x10-05	BI 2536
276	11	60102384	rs2304935	MS4A6E	G/A	175	2.27	0.566338	9.26 x10-05	BI 2536
277	7	151962257	rs62478357	MLL3	C/T	175	-4.17	1.04007	9.33 x10-05	Idarubicin
278	2	27438615	rs11556165	C2orf28	G/C	175	4.75	1.18635	9.39 x10-05	Belinostat
279	12	117160976	rs10507274	C12orf49	T/C	175	-5.20	1.29927	9.40 x10-05	Entinostat
280	1	41486245	rs1138293	SLFNL1	C/T	175	-4.53	1.13276	9.45 x10-05	Navitoclax
281	19	18375608	rs8102923	KIAA1683	G/A	175	-2.65	0.663864	9.50 x10-05	Gemcitabine
282	22	40075341	rs59504308	CACNA1I	C/T	173	-7.79	1.94851	9.56 x10-05	Idarubicin
283	4	57889677	rs1056364	POLR2B	T/C	175	0.84	0.211006	9.61 x10-05	Fingolimod
284	2	103335646	rs115622745	MFSD9	A/G	174	6.27	1.56948	9.78 x10-05	Belinostat
285	17	34341398	rs61737011	CCL23	A/G	175	-3.62	0.906347	9.79 x10-05	Bortezomib

286	1	183072701	rs2296289	LAMC1	C/T	175	4.05	1.01454	9.81 x10-05	Luminespib
287	9	137593099	rs138579182	COL5A1	G/A	175	6.07	1.52006	9.81 x10-05	Pictilisib
288	1	186022964	rs144191448	HMCN1	A/G	175	3.11	0.779314	9.82 x10-05	Fingolimod
289	1	186031713	rs148467349	HMCN1	G/A	175	3.11	0.779314	9.82 x10-05	Fingolimod
290	18	47796017	rs72923678	MBD1	G/A	175	-8.17	2.048	9.84 x10-05	Panobinostat
291	16	79245687	rs199576434	WVOX	C/T	174	-8.35	2.09269	9.85 x10-05	Belinostat
292	11	1263687	rs55933911	MUC5B	C/T	175	2.25	0.563395	9.87 x10-05	Palbociclib
293	14	24035079	rs140983547	AP1G2	C/T	175	3.11	0.780317	9.87 x10-05	Alvocidib
294	3	36931397	rs74424604	TRANK1	C/T	175	6.05	1.52	9.91 x10-05	Valrubicin
295	4	183664522	rs7654255	ODZ3	T/C	175	2.10	0.526866	9.99 x10-05	Alvocidib